Pancreatic ductal adenocarcinoma: metastatic disease

• A. J. Muñoz Martín ^[1] ; J. Adeva ^[2] ; J. Martínez-Galán ^[3] ; J. J. Reina ^[5] ; M. Hidalgo ^[4]
  1. [1] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  2. [2] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  3. [3] Hospital Universitario Virgen de las Nieves

     Hospital Universitario Virgen de las Nieves

     Granada, España

     
  4. [4] Beth Israel Deaconess Medical Center

     Beth Israel Deaconess Medical Center

     City of Boston, Estados Unidos

     
  5. [5] Hospital Universitario Virgen de la Macarena. Sevilla

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 12, 2017, págs. 1423-1429
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called “therapeutic sequencing” has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient’s characteristics.